Baxter International (BAX Quick QuoteBAX - Free Report) reported $2.81 billion in revenue for the quarter ended June 2025, representing a year-over-year decline of 26.3%. EPS of $0.59 for the same period compares to $0.68 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $2.82 billion, representing a surprise of -0.28%. The company delivered an EPS surprise of -1.67%, with the consensus EPS estimate being $0.60.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Baxter performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Net Sales- Pharmaceuticals- U.S.: $187 million versus $201.97 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -5.1% change.
• Net Sales- Pharmaceuticals- International: $425 million versus $434.72 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +4.9% change.
• Net Sales- Healthcare Systems and Technologies- International: $205 million versus the three-analyst average estimate of $198.81 million. The reported number represents a year-over-year change of +3.5%.
• Net Sales- Care and Connectivity Solutions- International: $133 million versus $119.15 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +10.8% change.
• Net Sales- Pharmaceuticals: $612 million versus the five-analyst average estimate of $628.29 million. The reported number represents a year-over-year change of +1.7%.
• Net Sales- Advanced Surgery: $296 million compared to the $285.18 million average estimate based on five analysts. The reported number represents a change of +6.9% year over year.
• Net Sales- Other: $111 million versus $80.76 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +404.6% change.
• Net Sales- Front Line Care: $293 million versus the five-analyst average estimate of $299.81 million. The reported number represents a year-over-year change of -1%.
• Net Sales- Infusion Therapies and Technologies: $1.02 billion versus the five-analyst average estimate of $1.06 billion. The reported number represents a year-over-year change of -2%.
• Net Sales- Healthcare Systems and Technologies: $767 million versus $753 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +2.5% change.
• Net Sales- Care and Connectivity Solutions: $474 million compared to the $456.39 million average estimate based on five analysts. The reported number represents a change of +4.9% year over year.
• Net Sales- Medical Products and Therapies: $1.32 billion versus the five-analyst average estimate of $1.35 billion. The reported number represents a year-over-year change of -0.2%.

View all Key Company Metrics for Baxter here>>>

Shares of Baxter have returned -9.9% over the past month versus the Zacks S&P 500 composite's +2.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.